LIONLion Capital S.A.
4.920RON+0.61%Mkt Cap: 535.09M $P/E: 3.62

SIF Banat-Crisana is a self-managed closed-end investment company and since March 2018, it is authorized by ASF as alternative investment fund manager. The firm targets the maximizing of portfolio performance, thus incre…

HeadlineSourceTime
Yesterday
Ziarul Financiar
This week
BBusinessMagazin
Ziarul Bursa
FFinancial Intelligence
Profit.ro
Ziarul Financiar
FForbes Romania
Older
1asig.ro
DDCBusiness
FFinancial Intelligence
Ziarul Bursa
Ziarul Financiar
Ziarul Financiar
Ziarul Bursa
Profit.ro
Heineken’s Strongbow adds NaviLens levels to packaging

The cider brand has added a high-contrast NaviLens QR code to its cans.

Packaging Gateway
3 firms to lay off hundreds of North Jersey-based employees

BioReference health, JPMorgan Chase and an Italian fashion retailer are making the job cuts amid market uncertainty

The Bergen Record
Novartis to acquire Tourmaline Bio for $1.4 billion

Novartis will acquire Tourmaline Bio for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on Tuesday. Tourmaline is focused on developing pacibekitug, a promising targeted therapy with the potential to reduce systemic inflammation, as a treatment option for atherosclerotic cardiovascular disease, Novartis said in a statement. With the deal, Novartis will acquire a Phase III-ready asset that will complement its existing cardiovascular disease portfolio, it said.

Reuters
Novartis to acquire Tourmaline Bio for $1.4 billion

Novartis will acquire Tourmaline Bio for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on Tuesday. Tourmaline is focused on developing pacibekitug, a promising targeted therapy with the potential to reduce systemic inflammation, as a treatment option for atherosclerotic cardiovascular disease, Novartis said in a statement. With the deal, Novartis will acquire a Phase III-ready asset that will complement its existing cardiovascular disease portfolio, it said.

Reuters